The safety of tranexamic acid in cancer patients generally depends on individual circumstances, including the type and stage of cancer, the presence of any coagulopathies, and concurrent treatments. While it is considered relatively safe, there are concerns about the potential risk of thromboembolic events, particularly in patients already predisposed to clotting disorders.
